Literature DB >> 27169082

Effect of Alpha-1-Adrenergic Agonist, Midodrine for the Management of Long-Standing Neurogenic Shock in Patient with Cervical Spinal Cord Injury: A Case Report.

Taikwan Kim1, Cheol Su Jwa1.   

Abstract

We report a rare case of a 71-year-old male patient who had suffered from long-lasting neurogenic shock for 13 weeks after cervical spinal cord injury (SCI) caused by a bicycle accident. The neurogenic shock was resolved dramatically 2 weeks after the administration of alpha-1-adrenergic agonist, midodrine hydrochloride. In usual cases, neurogenic shock tends to improve between 2 and 6 weeks after SCI; however, in a few cases, the shock lasts for several months. In our case, spinal shock lasted for 13 weeks and exhibited very sensitive decline of blood pressure for even a slight decrease of dopamine despite recovered bulbospongiosus reflex. Three days after midodrine hydrochloride was added, hypotension improved dramatically. We discuss our rare case with pertinent literatures.

Entities:  

Keywords:  Adrenergic alpha-agonists; Hypotension; Midodrine; Spinal cord injuries

Year:  2015        PMID: 27169082      PMCID: PMC4847524          DOI: 10.13004/kjnt.2015.11.2.147

Source DB:  PubMed          Journal:  Korean J Neurotrauma        ISSN: 2234-8999


  10 in total

Review 1.  Clinical practice. Neurogenic orthostatic hypotension.

Authors:  Roy Freeman
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

2.  Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins.

Authors:  O Thulesius; J E Gjöres; E Berlin
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

Review 3.  Cardiovascular and urological dysfunction in spinal cord injury.

Authors:  E M Hagen; S Faerestrand; J M Hoff; T Rekand; M Gronning
Journal:  Acta Neurol Scand Suppl       Date:  2011

4.  Midodrine for the management of orthostatic hypotension in patients with spinal cord injury: A case report.

Authors:  J Mukand; L Karlin; K Barrs; P Lublin
Journal:  Arch Phys Med Rehabil       Date:  2001-05       Impact factor: 3.966

Review 5.  Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury.

Authors:  R W Teasell; J M Arnold; A Krassioukov; G A Delaney
Journal:  Arch Phys Med Rehabil       Date:  2000-04       Impact factor: 3.966

Review 6.  Midodrine hydrochloride and the treatment of orthostatic hypotension in tetraplegia: two cases and a review of the literature.

Authors:  D B Barber; S J Rogers; M D Fredrickson; A C Able
Journal:  Spinal Cord       Date:  2000-02       Impact factor: 2.772

7.  Double-blinded, placebo-controlled trial of midodrine for exercise performance enhancement in tetraplegia: a pilot study.

Authors:  Edward C Nieshoff; Thomas J Birk; Cynthia A Birk; Steven R Hinderer; Gunes Yavuzer
Journal:  J Spinal Cord Med       Date:  2004       Impact factor: 1.985

8.  A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.

Authors:  R A Wright; H C Kaufmann; R Perera; T L Opfer-Gehrking; M A McElligott; K N Sheng; P A Low
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

Review 9.  Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders.

Authors:  D McTavish; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 10.  A systematic review of intensive cardiopulmonary management after spinal cord injury.

Authors:  Steven Casha; Sean Christie
Journal:  J Neurotrauma       Date:  2010-04-08       Impact factor: 5.269

  10 in total
  1 in total

Review 1.  Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis.

Authors:  Rahul Mittal; Luca H Debs; Amit P Patel; Desiree Nguyen; Kunal Patel; Gregory O'Connor; M'hamed Grati; Jeenu Mittal; Denise Yan; Adrien A Eshraghi; Sapna K Deo; Sylvia Daunert; Xue Zhong Liu
Journal:  J Cell Physiol       Date:  2017-04-10       Impact factor: 6.384

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.